このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Amphastar Pharmaceuticals 過去の業績
過去 基準チェック /66
Amphastar Pharmaceuticalsは、平均年間40.2%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 減少しています。収益は、平均年間0.4% 16%収益成長率で 成長しています。 Amphastar Pharmaceuticalsの自己資本利益率は23%であり、純利益率は22.9%です。
主要情報
40.2%
収益成長率
39.4%
EPS成長率
| Pharmaceuticals 業界の成長 | 6.0% |
| 収益成長率 | 16.0% |
| 株主資本利益率 | 23.0% |
| ネット・マージン | 22.9% |
| 前回の決算情報 | 31 Mar 2024 |
最近の業績更新
Recent updates
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
May 30
Amphastar Pharmaceuticals: Buy When Fear Is Overblown
May 30Reassessing Amphastar Pharmaceuticals
May 15Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Mar 04Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
Jan 04Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
Dec 20Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
Dec 03Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued
Sep 03These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Aug 17Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching
Jun 02We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
May 11Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price
Mar 02Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?
Feb 07Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?
Jan 24Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Nov 02Amphastar: A Pharmaceutical Growth Stock
Oct 06Amphastar wins FDA approval for Epinephrine pre-filled syringes
Aug 16Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond
Aug 08Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 24Amphastar generic vasopressin for increasing blood pressure gets FDA approval
Jul 19We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
Jun 10Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio
May 13I Ran A Stock Scan For Earnings Growth And Amphastar Pharmaceuticals (NASDAQ:AMPH) Passed With Ease
Apr 23These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Feb 13Amphastar Pharma: A Well-Run, Diversified Mid Cap
Jan 26収支内訳
収支内訳
Amphastar Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Mar 24 | 676 | 155 | 85 | 71 |
| 31 Dec 23 | 644 | 138 | 80 | 74 |
| 30 Sep 23 | 601 | 135 | 75 | 71 |
| 30 Jun 23 | 541 | 102 | 72 | 72 |
| 31 Mar 23 | 519 | 93 | 69 | 78 |
| 31 Dec 22 | 499 | 91 | 67 | 75 |
| 30 Sep 22 | 485 | 77 | 63 | 75 |
| 30 Jun 22 | 477 | 91 | 62 | 67 |
| 31 Mar 22 | 455 | 81 | 65 | 62 |
| 31 Dec 21 | 438 | 62 | 67 | 61 |
| 30 Sep 21 | 413 | 36 | 68 | 62 |
| 30 Jun 21 | 384 | 10 | 67 | 69 |
| 31 Mar 21 | 368 | 2 | 69 | 67 |
| 31 Dec 20 | 350 | 1 | 63 | 67 |
| 30 Sep 20 | 337 | 7 | 63 | 69 |
| 30 Jun 20 | 334 | 4 | 62 | 70 |
| 31 Mar 20 | 327 | 52 | 58 | 70 |
| 31 Dec 19 | 322 | 49 | 63 | 69 |
| 30 Sep 19 | 329 | 52 | 66 | 66 |
| 30 Jun 19 | 324 | 53 | 67 | 59 |
| 31 Mar 19 | 316 | 2 | 65 | 58 |
| 31 Dec 18 | 295 | -6 | 58 | 58 |
| 30 Sep 18 | 265 | -7 | 52 | 52 |
| 30 Jun 18 | 248 | -9 | 51 | 51 |
| 31 Mar 18 | 242 | -4 | 51 | 46 |
| 31 Dec 17 | 240 | 4 | 51 | 44 |
| 30 Sep 17 | 243 | 0 | 52 | 44 |
| 30 Jun 17 | 250 | 4 | 51 | 44 |
| 31 Mar 17 | 252 | 9 | 48 | 44 |
| 31 Dec 16 | 255 | 10 | 47 | 42 |
| 30 Sep 16 | 269 | 21 | 45 | 38 |
| 30 Jun 16 | 268 | 14 | 43 | 39 |
| 31 Mar 16 | 254 | 0 | 45 | 39 |
| 31 Dec 15 | 252 | -3 | 44 | 37 |
| 30 Sep 15 | 230 | -13 | 45 | 36 |
| 30 Jun 15 | 226 | -15 | 46 | 34 |
| 31 Mar 15 | 221 | -10 | 43 | 29 |
| 31 Dec 14 | 210 | -11 | 40 | 29 |
| 30 Sep 14 | 209 | -6 | 38 | 28 |
| 30 Jun 14 | 209 | -1 | 38 | 29 |
| 31 Mar 14 | 223 | 8 | 36 | 30 |
| 31 Dec 13 | 230 | 12 | 36 | 33 |
| 30 Sep 13 | 227 | 14 | 35 | 33 |
質の高い収益: AMPHは 高品質の収益 を持っています。
利益率の向上: AMPHの現在の純利益率 (22.9%)は、昨年(18%)よりも高くなっています。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: AMPHの収益は過去 5 年間で年間40.2%増加しました。
成長の加速: AMPHの過去 1 年間の収益成長率 ( 66% ) は、5 年間の平均 ( 年間40.2%を上回っています。
収益対業界: AMPHの過去 1 年間の収益成長率 ( 66% ) はPharmaceuticals業界19.9%を上回りました。
株主資本利益率
高いROE: AMPHの 自己資本利益率 ( 23% ) は 高い とみなされます。